|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
Mini Oral Session: GU Tumors, Prostate
|
|
| Duration of Androgen Suppression with Post-Operative Radiotherapy (DADSPORT): A Collaborative Meta-Analysis of Aggregate Data
|
| Sarah Burdett
|
| In this presentation, Sarah Burdett discusses DADSPORT, a collaborative meta-analysis of aggregate data to assess the duration of androgen suppression with post-operative radiotherapy. The DADSPORT meta-analysis collaboration conducted a systematic review and meta-analysis of results from NRG/RTOG 9601, GETUG-AFU 16, NRG/RTOG 0534, and the newly-available, RADICALS-HD trials to assess the effect of hormone therapy in men receiving radiotherapy following radical prostatectomy for localized prostate cancer.
|
|
|
|
|
|
| Differential Treatment Response with Nodal Metastases in mHSPC and Evaluation of Nodal Burden as a Prognostic Biomarker - Ancillary Studies of the Docetaxel and Abiraterone Acetate and Prednisolone Phase III Trials from STAMPEDE
|
| Áine Haran, BSc (Hons), BMBS, MRCS
|
| Áine Haran discusses the ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE, specifically the differential treatment response with nodal metastases in mHSPC and the evaluation of nodal burden as a prognostic biomarker.
|
|
|
|
|
|
| Presidential Symposiums |
| Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
|
| Robert J. Motzer, MD
|
| In the Presidential Symposium II at the European Society for Medical Oncology (ESMO) Annual Congress, Robert Motzer presented the highly awaited results from the CheckMate 914 trial, examining the role of adjuvant nivolumab and ipilimumab in patients treated with nephrectomy for localized renal cell carcinoma (RCC) at a high risk of relapse.
|
|
|
|
|
|
| Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of Imdc Intermediate- or Poor-Risk (COSMIC-313)
|
| Toni K. Choueiri, MD
|
| Toni Choueiri presented the highly awaited results from the COSMIC-313 trial, examining the role of triplet therapy with cabozantinib, nivolumab, and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma. Triplet combination of cabozantinib, nivolumab, and ipilimumab significantly improved progression-free survival compared to placebo, nivolumab and ipilimumab (a current standard of care) as first-line treatment for patients with IMDC intermediate or poor risk advanced RCC.
|
|
|
|
|
|
|
|
|
|
|
| Invited Discussant: Results of COSMIC-313
|
| Sumanta K. Pal, MD
|
| Following Dr. Toni Choueiri’s presentation of the results of COSMIC-313 examining the role of triplet therapy with cabozantinib, nivolumab, and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC), Dr. Sumanta Pal provided an invited discussion to contextualize these results.
|
|
|
|
|
|
| Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031 |
| Chris Parker, MD, FRCR, MRCP |
| Chris Parker presented results of the RADICALS-HD trial examining the effect of differing durations of androgen deprivation therapy (ADT) among men receiving post-operative radiotherapy following radical prostatectomy for prostate cancer. This is a key question as, though there is substantial high-quality evidence regarding the role and durations of ADT for men receiving primary radiotherapy for the treatment of prostate cancer, there is considerable uncertainty regarding its role and duration for men who are receiving post-prostatectomy radiotherapy. |
|
|
|
|
|
| Multidisciplinary Updates in Biomarkers in Urinary Cancers |
| Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers
|
| E. G. Elisabeth de Vries, MD, Ph.D.
|
| Elisabeth de Vries discussed the latest imaging advances in PET and beyond translated to bladder and kidney cancers. Dr. de Vries notes that molecular imaging takes advantage of tumor biology in vivo and numerous targets for ligands. With regards to PET imaging and translation to bladder and kidney cancers, the potential aim is to predict who will respond to what treatment and PET imaging.
|
|
|
|
|
|
| Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome
|
| Lisa Derosa
|
| Lisa Derosa discussed the importance of the microbiome. Dr. Derosa notes that we have identified a number of factors that impact tumor growth and response to cancer treatment, which now include polymorphic microbiomes. However, although the impact of the gut microbiome in genitourinary cancer immunotherapy was first studied, it was done serendipitously.
|
|
|
|
|
|
| Mini Oral Session: GU Tumors, Non-Prostate |
| Neoadjuvant Platinum-Based Chemotherapy (NAPC) for Metastatic Penile Squamous Cell Carcinoma (PSCC): An International, Multicenter, Real-World Study
|
| Jad Chahoud, MD, MPH
|
| Jad Chahoud presented a real-world analysis of neoadjuvant platinum-based chemotherapy (NAPC) in locally advanced squamous cell carcinoma of the penis. A benefit of this treatment approach has been previously suggested by prior small case series. Currently, this approach is being assessed in the phase III randomized InPACT trial. However, those data are not going to be available for at least 4 years. Thus, there is an ongoing evidence void.
|
|
|
|
|
|
| Outcomes of Relapsed Clinical Stage I Versus De Novo Metastatic Testicular Cancer Patients: An Analysis of the IGCCCG Update Database
|
| Prof. Dr. Med. Silke Gillessen
|
| During the Mini Oral session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate genitourinary cancers, Dr. Gillessen presented an analysis of the updated IGCCCG dataset assessing the prognostic effect of relapsed clinical stage I compared to de novo metastatic testicular cancer patients.
|
|
|
|
|
|
|
|
|
|
|
| Risk and Mortality of Testicular Cancer in Patients with Psychiatric or Neurodevelopmental Disorders
|
| Anna Jansson, MD
|
| Anna Jansson presented a population-based analysis assessing the association between psychiatric disorders, in particular neurodevelopmental disorders, and the risk of testicular germ cell cancer (TGCC), as well as mortality. Dr. Jansson concluded that this presentation represents the first identification of this novel association between neurodevelopmental disorders and testicular seminoma.
|
|
|
|
|
|
| The Challenges and Opportunities Present in the Treatment of Rare Genitourinary Cancers Discussion
|
| Aly-Khan Lalani, MD
|
| Following presentations from Dr. Chahoud discussing the role of neoadjuvant platinum-based chemotherapy in patients with metastatic penile squamous cell carcinoma, from Dr. Gillessen considering the prognostic implication of relapsed stage I compared to de novo, metastatic testicular cancer, and from Dr. Jansson considering both the risk of testicular cancer and its associated mortality in patients with psychiatric or neurodevelopmental disorders, Dr. Lalani provided an invited discussion to contextualize these results.
|
|
|
|
|
|
| Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
|
| Clarice Groeneveld, Ph.D.
|
| Clarice Groeneveld presented the results of an analysis of the effect of pure or mixed basal/squamous histology on the efficacy of neoadjuvant chemotherapy in muscle-invasive bladder cancer based on the GETUG-AFU V05 VESPER trial. Previous work has suggested that molecular subtyping of urothelial carcinoma may affect the outcomes after neoadjuvant chemotherapy, though this is controversial and results have been contradictory.
|
|
|
|
|
|
|
|
|
|
|
| Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial
|
| Andrea Necchi, MD
|
| Andrea Necchi presented results from the CheckMate 274 trial assessing tumor and immune features predictive of disease-free survival. CheckMate 274 randomized patients with high-risk muscle-invasive urothelial carcinoma after radical resection to receive adjuvant nivolumab or placebo, demonstrating improved disease-free survival with adjuvant nivolumab in the intent-to-treat and tumor PD-L1 expression ≥ 1% populations.
|
|
|
|
|
|
| Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial
|
| Michiel S. Van der Heijden, MD, Ph.D.
|
| Following presentations from Dr. Clarice Groeneveld discussing the association between underlying histology and response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC) in the phase III VESPER trial and from Dr. Andrea Necchi examining tumor and immune features predictive of disease-free survival in patients receiving adjuvant nivolumab following cystectomy in the phase III CheckMate 274 trial, Dr. Michiel Van der Heijden provided an invited discussion to contextualize these results.
|
|
|
|
|
|
|
